Idiopathic Pulmonary Fibrosis Treatment Market is expected to reach US$ 10,784.07 million by 2030

Publisher: The Insight Partners

Nintedanib Segment to Lead Global Idiopathic Pulmonary Fibrosis Treatment Market During 2022–2030

According to our new research study on “Idiopathic Pulmonary Fibrosis Treatment Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Drug Type and Distribution Channel,” the market is expected to grow from US$ 4,360.87 million in 2022 to US$ 10,784.07 million by 2030; it is estimated to register a CAGR of 12.0% during 2022–2030. The growth of the idiopathic pulmonary fibrosis treatment market is attributed to the growing burden of idiopathic pulmonary fibrosis and an increasing number of people smoking cigarettes. An upsurge in research and development activities, coupled with technological advancements, to treat fibrosis is expected to create growth opportunities in the market in the coming years. Nonetheless, the lack of awareness and unavailability of proper treatment options hinder the idiopathic pulmonary fibrosis treatment market growth.

Idiopathic pulmonary fibrosis is a chronic condition that affects the tissue surrounding the alveoli in the lungs. It develops when lung tissues become stiff and thick for unknown reasons, and these changes result in permanent scarring in the lungs over time, which makes breathing difficult among patients. Currently, there is no precise cure for idiopathic pulmonary fibrosis. Treatments such as pulmonary rehabilitation, medicines, and surgical procedures slow down lung damage and help enhance the quality of patients’ lives.

Idiopathic Pulmonary Fibrosis Treatment Market, by Region, 2022 (%)

Source: The Insight Partners Analysis

The growth of the idiopathic pulmonary fibrosis market is driven by the growing burden of idiopathic pulmonary fibrosis and an increase in the number of people smoking cigarettes. A surging number of research and development activities, coupled with technological advancements in treatment options, is expected to provide growth opportunities for the idiopathic pulmonary fibrosis treatment market in the coming years. While inventions are important, upgrading existing products is equally important in treating disorders that have no direct cure, as consumer preferences may frequently change. Only a few drug treatment options are available against idiopathic pulmonary fibrosis, which include the administration of pirfenidone and nintedanib. Therefore, research and development activities to introduce drugs and treatment options act as significant opportunities for the idiopathic pulmonary fibrosis treatment market players.  

Based on drug type, the idiopathic pulmonary fibrosis treatment market is segmented into nintedanib, pirfenidone, and others. The nintedanib segment held a larger market share in 2022. The others segment is anticipated to register a higher CAGR of 46.3% during 2022–2030. Pirfenidone and nintedanib are the popular medicines prescribed to treat fibrotic diseases.

The idiopathic pulmonary fibrosis treatment market, by distribution channel, is categorized into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held the largest market share in 2022. The online pharmacies segment is anticipated to register the highest CAGR of 17.4% during 2022–2030.

Lack of Effective Biomarkers and Diagnostic Tools for Early Detection and Monitoring, and High Cost of Treatments Hinder Idiopathic Pulmonary Fibrosis Treatment Market Growth 

Biomarkers play a major role in measuring physiological and pathological processes or effects of drugs. For example, they can help diagnose diseases; predict mortality, exacerbation, and disease progression (prognosis); and estimate response to therapies (theranostics). High-resolution computed tomography of the lung is the main diagnostic test for idiopathic pulmonary fibrosis. The limited availability of chest imaging techniques and limited access to biomarkers are among the major barriers to the diagnosis of this condition, especially in developing countries. Furthermore, taking pulmonary function tests that produce reliable results and accessing treatments is troublesome in rural areas. Adding to the plight, the costs of treatments for idiopathic pulmonary fibrosis are increasing continuously. The modern technological devices used in fibrosis treatment contribute significantly to the high treatment cost. Therefore, the dearth of effective biomarkers and diagnostic tools for early detection and monitoring, and the elevated costs associated with medication and treatment hamper the growth of the idiopathic pulmonary fibrosis treatment market.

Genentech, Inc. and Boehringer Ingelheim International GmbH are among the leading idiopathic pulmonary fibrosis treatment market players.

The idiopathic pulmonary fibrosis treatment market is segmented on the basis of drug type and distribution channel. The market, by drug type, is segmented into nintedanib, pirfenidone, and others. The idiopathic pulmonary fibrosis treatment market, by distribution channel, is categorized into hospital pharmacies, retail pharmacies, and online pharmacies. In terms of geography, the idiopathic pulmonary fibrosis treatment market is segmented into North America (US, Canada, and Mexico), Europe (France, Germany, UK, Spain, Italy, and Rest of Europe), Asia Pacific (China, India, Japan, Australia, South Korea, and Rest of Asia Pacific), the Middle East & Africa (Saudi Arabia, UAE, South Africa, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).

Contact Us
Contact Us: The Insight Partners 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com